on CPAP therapy were recruited. Eleven were randomised to continue on CPAP for 2 weeks as the control, and 12 were randomised to receive sham CPAP for 2 weeks, i.e. CPAP withdrawal, in a double-blinded manner [6] . Participants were well matched for age [CPAP mean 59 (SD 7.8) years old, sham CPAP 61.1 (8.9) years old], original OSA severity (established by having withdrawn CPAP for 4 nights prior to the actual trial to prove that their OSA did indeed return), oxygen desaturation index (ODI) [CPAP 53.1 (14.5), sham CPAP 54.6 (22.0)] and BMI [CPAP 36.8 (7.4), sham CPAP 36.9 (7.5)]. CPAP withdrawal led to a rise in ODI of >4% from 3.1 (3.2)/h to 43.0 (24.2)/h, whereas the ODI in the control group remained unchanged as expected.
In 2013 we reported that in patients with obstructive sleep apnoea (OSA), withdrawing their continuous positive airway pressure (CPAP) therapy for 2 weeks led to a significant increase in endothelial cell-derived microvesicles (MVs) [1] . Several other studies have found that the initiation of CPAP therapy in patients with OSA leads to a fall in endothelial [2, 3] and platelet [4, 5] MVs, but there have been no further studies investigating the impact of CPAP withdrawal in patients established on therapy, which provides a more robust experimental protocol. Therefore, in this further exploratory study we have examined the impact of CPAP withdrawal on other subtypes of MVs.
Fourteen of the patients in this study were included in a previously published study, where the primary outcome measure was a marker of oxidative stress (PMID 26022961) and this publication includes the full protocol. A total of 23 OSA patients established 413 tion, inflammatory and atherogenic processes potentially providing a link between OSA and cardiovascular disease. The findings that successful CPAP therapy reduces platelet MV levels, and the withdrawal of this CPAP leads to an elevation, as shown in the current study, suggests that platelet MVs are a potential biomarker of an OSA-induced effect on atherogenic processes, and that therapy can reduce them. Leucocyte MVs have also been shown to be elevated in untreated OSA patients [8] and a correlation was noted with the apnoeahypopnoea index in children with OSA [9] . Leucocyte MVs are present at high levels in patients with atherosclerosis and diabetes, and they are thought to be involved in the processes of inflammation, thrombosis and endothelial dysfunction [10] .
Although there is a paucity of robust randomised and controlled studies and conflicting data, CPAP therapy and the consequent reduction in intermittent hypoxia and catecholamine levels may reduce platelet activation [11] and inflammation [12] , processes thought to trigger MV release, thus potentially explaining the changes in circulating MVs found with the commencing or withdrawal of CPAP. Thus, CPAP therapy may reduce the risk of patients developing co-morbidities such as cardiovascular disease [13] , and if this link is firmly established, then lowered circulating MVs may be a part of the explanation. However, the true causal nature of MVs in the pathogenesis of vascular co-morbidities linked to OSA requires further investigation.
